$12.53
3.24% yesterday
Nasdaq, Sep 18, 10:00 pm CET
ISIN
US75901B1070
Symbol
RGNX
Sector
Industry

REGENXBIO, Inc. Stock price

$12.53
+0.05 0.40% 1M
-9.80 43.89% 6M
-5.42 30.20% YTD
-5.28 29.65% 1Y
-31.05 71.25% 3Y
-26.08 67.55% 5Y
-17.92 58.85% 10Y
Nasdaq, Closing price Wed, Sep 18 2024
-0.42 3.24%
ISIN
US75901B1070
Symbol
RGNX
Sector
Industry

Key metrics

Market capitalization $619.27m
Enterprise Value $487.63m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.48
P/S ratio (TTM) P/S ratio 6.96
P/B ratio (TTM) P/B ratio 1.77
Revenue growth (TTM) Revenue growth -8.18%
Revenue (TTM) Revenue $89.04m
EBIT (operating result TTM) EBIT $-246.66m
Free Cash Flow (TTM) Free Cash Flow $-194.72m
Cash position $290.36m
EPS (TTM) EPS $-5.27
P/E forward negative
P/S forward 6.91
EV/Sales forward 5.49
Short interest 16.08%
Show more

Is REGENXBIO, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

REGENXBIO, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a REGENXBIO, Inc. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a REGENXBIO, Inc. forecast:

Buy
100%

Financial data from REGENXBIO, Inc.

Assets
Dec '23
335 335
Cash 275 275
Claims 26 26
Inventories - -
Other current assets Other current assets Current assets 33 33
239 239
Property, plant and equipment 193 193
Financial assets 42 42
Intangible Assets - -
Other fixed assets Other assets Fixed assets 4.81 4.81
Total Assets 574 574
Liabilities
Dec '23
Equity 312 312
262 262
Current liabilities 130 130
Non-current liabilities 132 132
Total Capital 574 574

In millions USD.

Don't miss a Thing! We will send you all news about REGENXBIO, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

REGENXBIO, Inc. Stock News

Neutral
PRNewsWire
one day ago
Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programs Vit Vasista steps down following more than 15 years at the Company ROCKVILLE, Md. , Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today.
Positive
24/7 Wall Street
10 days ago
Among the Wall Street firms investors often pay closest attention to, Goldman Sachs (NYSE:GS) has to be atop the list.
Neutral
PRNewsWire
16 days ago
-  Data from pivotal dose level demonstrates long-term, sustained reductions in CSF levels of HS D2S6, a key biomarker of brain disease in MPS II -  80% of patients who received the pivotal dose discontinued intravenous enzyme replacement therapy or remained treatment-naïve -  Submission of a rolling BLA using the accelerated approval pathway on track for Q3 2024 ROCKVILLE, Md. , Sept. 3, 2024 ...
More REGENXBIO, Inc. News

Company Profile

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Head office United States
CEO Curran Simpson
Employees 344
Founded 2008
Website www.regenxbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today